KAP Survey

How often do you prescribe SGLT2 inhibitors to patients with Type 2 Diabetes?

• Very Frequently (more than 75% of the time)

• Frequently (50-75% of the time)

• Occasionally (less than 50% of the time)

• Rarely or never

Which SGLT2 inhibitors do you typically prescribe in patients of Heart Failure?

• Canagliflozin

• Empagliflozin

• Dapagliflozin

• Ertugliflozin

What factors do you consider when deciding whether to prescribe SGLT2 inhibitors to a patient? Please select all that apply.

• Patient's glycemic control

• Cardiovascular risk factors

• Renal function

• Presence of heart failure

• Patient's weight

Diabetic patients are usually coming with comorbid conditions, do you think price should be a consideration in choosing the choice of therapy?

• Yes

• No

The Comorbid disease burden in DM Type 2 patient is higher in

• Male

• Female

• Both

Most common comorbid in type 2 DM patient’s are: Select all that apply

• CVS/Hypertension

• Overweight/Obesity

• Chronic Kidney Disease

• Hyperuricemia

In your experience, how effective are SGLT2 inhibitors in promoting weight loss in patients with Type 2 Diabetes?

• Very Effective

• Somewhat Effective

• Not Effective

Does SGLT2 reduces length of stay during hospitalization?

• Significantly

• Moderately

• Not significantly

How confident are you in the combination therapy of Empagliflozin and Metformin as a treatment option for T2DM in Kidney and cardiac compromised patients?

• Very confident

• Confident

• Neutral

• Not-confident

While selecting Empagliflozin and metformin what is the expected therapy outcome?

• Improved glycemic control

• Reduced cardiovascular risk

• Improved renal function

• All of the above